1. South Korea Stocks

  2. •

    Electronic technology

  3. •

    Electronic equipment/Instruments
SD Biosensor, Inc.

SD Biosensor, Inc.

KKRX:137310
6,850.00
KRW
+100.00
(+1.48%)
-6,107.14EPS
763.17BMarket Cap
Nov 16Next Earn
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
879.29
18,068.5
30,043.34
28,944.82
5,914.54
5,681.61
5,937.39
6,171.26
Basic EPS, GAAP
38
6,597
11,161
8,997
-4,219
-805
-4,279
-6,093.82
Free Cash Flow per Basic Share
-110
4,717.42
11,644.78
5,810.25
-3,491.02
618.61
2,506.93
89.55
Dividend per Share
- -
- -
510.96
1,961.92
266.55
0.31
202.07
0.4
Book Value per Share
1,429.57
8,015.86
21,943.04
28,794.15
23,079.02
24,236.47
19,475.81
20,062.2
Tangible Book Value per Share
1,369.84
7,956.73
21,566.89
28,135.3
7,219.97
6,872.37
8,964.52
9,085.09
Basic Weighted Avg Shares
83
93
98
101
111
122
120
120
Sales/Revenue/Turnover
72,962
1,686,163
2,929,961
2,932,001
655,677
694,574
710,581
738,760
Operating Margin (%)
2.08
43.78
47.36
39.11
-37.84
-7.78
-11.39
-8.75
Depreciation Expense
4,331
7,974
19,115
40,820
137,541
141,694
134,266
125,725
Net Income, GAAP
3,153
615,636
1,088,471
911,362
-467,712
-98,411
-512,106
-729,491
Effective Tax Rate (%)
- -
13.33
25.7
26.83
- -
- -
- -
- -
Profit Margin (%)
4.32
36.51
37.15
31.08
-71.33
-14.17
-72.07
-98.75
Working Capital
78,668
599,859
1,826,919
2,220,286
644,212
761,830
766,563
773,014
LT Debt
2,785
14,536
18,378
11,729
467,533
599,424
357,369
277,566
Total Equity
137,914
757,551
2,232,209
2,946,781
2,831,546
2,932,281
2,336,866
2,405,761
Return on Invested Capital (%)
- -
123.58
59.11
29.18
- -
- -
- -
- -
Return on Capital (%)
- -
131.11
71.77
34.99
- -
- -
- -
- -
Return on Common Equity (%)
- -
139.69
73.36
35.3
-16.22
-3.42
-19.5
-26.91

Capital Structure

KRW

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
311,659
7,578
7,542
LT Borrowings
346,845
291,810
266,678
LT Finance Leases
10,524
10,227
10,888
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
120
120
120
Market Capitalization
1,064,611
915,087
763,171

Working Capital

KRW

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
1,232,814
960,277
913,314
Cash, Cash Equivalents & STI
774,175
497,602
449,515
Accounts Receivable, Net
138,069
141,197
140,700
Inventories
222,115
239,453
246,775
Total Current Liabilities
466,251
189,330
140,300
Payables & Accruals
- -
- -
- -
ST Debt
311,659
7,578
7,542
Deferred Revenue
- -
- -
- -

Growth Rates

KRW

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
41.2%
-20.31%
Free Cash Flow
- -
24.25%
296.73%
Net Income, GAAP
- -
50.13%
420.38%
Sales/Revenue/Turnover
- -
0.88%
2.3%
Total Cash Common Dividend
- -
- -
63,430.37%

Quarterly Revenue

KRW

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
176,389
167,461
170,606
180,118
694,574
2025
185,326
166,501
164,188
194,566
710,581
2026
193,529
186,477
- -
- -
- -

Quarterly Earnings Per Share

KRW

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
-91
-153
532
-1,093.12
-805
2025
-156
2,301
-81
-6,344.64
-4,279
2026
189.81
137.64
- -
- -
- -

Quarterly Dividends Per Share

KRW

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
0.31
2025
0.16
201.62
-0.01
0.41
202.07
2026
- -
- -
- -
- -
- -

Company Description

Company Profile APIChatGPT
CEO
Hyo-Geun Lee
Full Time Employees
656
Sector
Electronic technology
Industry
Electronic equipment/Instruments
Address
16 Deokyeong-daero Suwon-si GY South Korea 16690
IPO Date
Jul 16, 2021
Website
sdbiosensor.co.kr
Similar Companies
Advantest Corp. (TSE:6857)
Unusual Machines, Inc. (AMEX:UMAC)
FuelCell Energy, Inc. (NASDAQ:FCEL)
Lasertec Corp. (TSE:6920)
Hitachi Energy India Limited (NSE:POWERINDIA)
Keysight Technologies Inc. (NYSE:KEYS)
Business
SD BioSensor, Inc. (137310.KS) is a South Korea-based in vitro diagnostics company that develops, manufactures and markets point-of-care diagnostic solutions for infectious diseases, chronic conditions and general health screening; its core product platforms include STANDARD Q rapid diagnostic tests for parameters such as COVID-19, influenza and other infectious agents; STANDARD F fluorescent immunoassay systems for multi-parametric laboratory testing; STANDARD E enzyme-linked immunosorbent assays for mass screening; STANDARD M and M10 point-of-care molecular diagnostic systems with qPCR reagents and nucleic acid extraction kits for near-patient clinical decisions; STANDARD i chemiluminescent immunoassay analyzers; procell Dx interferon gamma release assays for tuberculosis and immune status evaluation; and blood glucose monitoring systems including meters like SD GlucoNavii with NFC connectivity for self-testing. Founded in 2010 and headquartered in Suwon, Gyeonggi-do, South Korea, the company operates globally with production facilities including a new plant in Gurugram, India that boosts annual capacity by over 2.9 times, serving markets in Asia, Europe, the Americas and low- and middle-income countries through distributors and subsidiaries. In recent developments, SD BioSensor completed its 2023 acquisition of a 60% stake in Meridian Bioscience, Inc. for $1.53 billion in partnership with SJL Partners to expand U.S. diagnostics capabilities; signed a December 2024 tripartite MOU with Japan's RIT/JATA and Korea's ITRC for R&D of M10 platform-based tests targeting extensively drug-resistant tuberculosis; secured WHO and Medicines Patent Pool sublicensing for rapid diagnostic technology transfer to Codix Bio in Nigeria in May 2025; launched 28 new products including STANDARD M10 in 2024 with KRW 87.9 billion R&D investment; obtained European CE-IVDR certifications for five blood glucose meters and molecular diagnostics in 2025; and participated in events like the 2025 Fall Conference of Korean Clinical Hypertension Society while planning a continuous glucose monitoring system rollout.